DoW Toxic Exposures Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Offered by Defense Health Agency Contracting Activity - DHACA; awards $4.5M; applications due November 19, 2026.
Key Facts
- Funder
- Defense Health Agency Contracting Activity - DHACA
- Award amount
- $4.5M
- Deadline
- November 19, 2026
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed...
Full requirements and application instructions: official listing.
Similar Open Grants
DoW Neurofibromatosis Investigator-Initiated Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Research Academy – Scholar Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Exploration-Hypothesis Development Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
Defense Health Agency Contracting Activity - DHACA
DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DOW Combat Readiness – Medical Research Program Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Toxic Exposures Investigator Initiated Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Toxic Exposures Translational Research Award
Defense Health Agency Contracting Activity - DHACA
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health